Glioblastoma in the Language Area Resected While Patient Spoke | 41-Year-Old Engineer's Function Preserved | Dr. Zhou Liangfu | China Medical Concierge - Shanghai

"A 5.6 Centimeter Tumor Growing Into the Part of His Brain That Made Him Who He Was. He Was 41. He Wrote Algorithms for a Living. He Needed His Words and His Right Hand. Both Were at Risk."

Mr. Li had always lived in his mind.

A 41-year-old algorithm engineer, he had built his career on the precision of his thinking - on the ability to hold complex systems in his head, to find the elegant solution, to communicate it clearly to his team. Language and executive function were not just professional tools for him. They were the architecture of his identity.

The symptoms had started two months before he came to Shanghai. A progressive weakness in his right leg that he had initially attributed to long hours at his desk. Then the word-finding difficulties - reaching for a term that should have been immediate and finding nothing, or finding the wrong word, or finding a word that was close but not right. Then three episodes of focal seizures affecting the right side of his face. He knew something was wrong in a way that went beyond the physical.

The MRI confirmed it: a 5.6 x 4.8 x 3.9 cm irregular enhancing mass in the left frontotemporal lobe, with central necrosis, surrounding T2/FLAIR hyperintense edema, and significant mass effect. The enhancement crossed the left Sylvian fissure and involved the superficial insula. Functional MRI showed that the posterior inferior frontal gyrus (Broca's area) and the supplementary motor area - the regions that generate and coordinate speech - had activation foci that partially overlapped with the tumor's posterior margin. DTI fiber tractography showed the left arcuate fasciculus compressed and displaced medially, and the corticospinal tract (CST) displaced inferolaterally but not interrupted. ASL perfusion showed markedly elevated rCBV, consistent with high-grade glioma.

Pre-operative neuropsychological assessment confirmed the clinical picture: Boston Naming Test Z-score -1.4, with mild executive function decline. KPS 90.

The multidisciplinary team - neurosurgery, neuroimaging, neurophysiology, neuro-oncology, and rehabilitation - reviewed his case together. Their consensus was unambiguous: high suspicion for WHO CNS Grade 5 glioblastoma, IDH wild-type; tumor located in dual eloquent cortex (language and motor); clear indication for maximal safe resection with awake craniotomy and biphasic cortical and subcortical electrophysiological mapping, targeting an extent of resection above 95% while preserving language and motor pathways.

His family brought him to Shanghai and sought care from Dr. Zhou Liangfu, former Chief of Neurosurgery at Huashan Hospital, Fudan University, through China Medical Concierge - Shanghai (CMCS).

Understanding Eloquent Cortex Glioblastoma Surgery: Why Awake Craniotomy Changes Everything

Glioblastoma is the most aggressive primary brain tumor in adults - but the extent of surgical resection is one of the strongest modifiable predictors of survival. In tumors involving eloquent cortex, the challenge is achieving maximum resection without causing the neurological deficits that would destroy the patient's quality of life and functional independence:

• Extent of resection is a critical determinant of survival in glioblastoma - multiple retrospective and prospective studies have demonstrated that greater extent of resection (EOR) is independently associated with longer overall survival and progression-free survival in glioblastoma; achieving EOR above 95% - near-total resection - is associated with significantly better outcomes than subtotal resection, even after controlling for molecular markers and adjuvant therapy; the survival benefit of maximal resection is particularly pronounced in IDH wild-type GBM, where the tumor's aggressive biology makes every additional month of disease control clinically meaningful
• Awake craniotomy with cortical mapping is the gold standard for eloquent cortex tumor resection - conventional resection under general anesthesia cannot distinguish functional cortex from tumor tissue in real time; awake craniotomy allows the surgeon to stimulate the cortex with a bipolar electrode while the patient performs language and motor tasks, identifying the precise boundaries of functional tissue that must be preserved; this real-time functional mapping enables resection to proceed to within millimeters of eloquent cortex without causing permanent deficit - a precision that is simply not achievable under general anesthesia
• Subcortical mapping extends functional preservation into the white matter pathways - cortical mapping identifies the surface location of functional areas, but the white matter tracts that connect them - the arcuate fasciculus for language, the corticospinal tract for motor function - run beneath the cortex and are equally critical to preserve; subcortical bipolar stimulation during tumor resection allows the surgeon to track these pathways in real time, stopping resection in any direction where stimulation produces a language or motor response; this subcortical mapping is the technical advance that makes near-total resection of deep eloquent cortex tumors possible without permanent deficit
• 5-ALA fluorescence guidance maximizes tumor visualization during resection - 5-aminolevulinic acid (5-ALA) is a prodrug that accumulates selectively in high-grade glioma cells and fluoresces pink-red under blue-violet light; intraoperative 5-ALA fluorescence allows the surgeon to visualize tumor tissue that appears identical to normal brain under white light, enabling more complete resection of infiltrating tumor margins; 5-ALA fluorescence guidance has been shown in randomized trials to significantly increase the proportion of patients achieving complete contrast-enhancing tumor resection
• Multimodal neuronavigation integrates functional and structural imaging for pre-resection planning - 3D neuronavigation systems that fuse T1 contrast-enhanced MRI, DTI fiber tractography, fMRI activation maps, and white matter atlas data allow the surgeon to plan the craniotomy, approach trajectory, and resection boundaries before the first incision; this pre-operative planning defines the expected location of eloquent cortex and critical white matter tracts, guiding the intraoperative mapping strategy and reducing the time required for real-time functional identification
• MGMT promoter methylation status guides adjuvant therapy selection in GBM - MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation silences the DNA repair enzyme that confers resistance to temozolomide; patients with MGMT-methylated GBM derive significantly greater benefit from temozolomide chemotherapy than unmethylated patients; in MGMT-unmethylated GBM, tumor treating fields (TTFields) - a device-based therapy that disrupts tumor cell division through alternating electric fields - has demonstrated survival benefit in the EORTC 22921 trial and is recommended as an adjunct to standard Stupp protocol in eligible patients
• The Asleep-Awake-Asleep anesthetic technique enables safe and cooperative awake craniotomy - the AAA technique uses total intravenous anesthesia (propofol plus remifentanil) for the opening and closing phases, with transition to a cooperative sedation state (dexmedetomidine with light propofol background) for the mapping and resection phase; this technique allows the patient to be fully cooperative for language and motor tasks during the critical resection phase while remaining comfortable and free of anxiety, without the airway management challenges of purely awake techniques

About Dr. Zhou Liangfu

Dr. Zhou Liangfu is the former Chief of Neurosurgery at Huashan Hospital, Fudan University - China's highest-volume neurosurgical center and one of the most experienced brain tumor surgery programs in the world. A pioneer in awake craniotomy and eloquent cortex tumor resection in China, Dr. Zhou is widely regarded as the father of modern Chinese neurosurgery. His decades of experience in functional neurosurgery, combined with Huashan Hospital's institutional infrastructure for multimodal neuronavigation, intraoperative neurophysiology, and 5-ALA fluorescence guidance, make him the destination surgeon for patients with brain tumors in or adjacent to eloquent cortex.

His clinical expertise spans:

• Awake craniotomy with cortical and subcortical mapping for eloquent cortex tumors - maximal safe resection of gliomas, meningiomas, and metastases involving language cortex (Broca's and Wernicke's areas), motor cortex, and their connecting white matter pathways (arcuate fasciculus, corticospinal tract, superior longitudinal fasciculus); Dr. Zhou's program achieves EOR rates and functional preservation outcomes that benchmark against the world's leading functional neurosurgery centers
• 5-ALA fluorescence-guided glioma resection - intraoperative 5-ALA fluorescence guidance for high-grade glioma resection, maximizing visualization of infiltrating tumor margins and increasing the proportion of patients achieving complete contrast-enhancing tumor removal
• Multimodal neuronavigation and intraoperative imaging - 3D neuronavigation integrating T1 contrast MRI, DTI fiber tractography, fMRI activation maps, and ASL perfusion data; intraoperative MRI for real-time resection extent assessment and navigation update in selected cases
• Complex skull base and deep-seated tumor surgery - microsurgical resection of skull base meningiomas, acoustic neuromas, pituitary adenomas, and deep-seated gliomas involving the insula, thalamus, and basal ganglia; Dr. Zhou's skull base experience spans four decades and encompasses the full spectrum of complex intracranial pathology
• Pediatric and adult brain tumor surgery - surgical management of the full spectrum of primary and metastatic brain tumors across age groups, including medulloblastoma, ependymoma, craniopharyngioma, and brain metastases from systemic malignancies
• Neuro-oncology multidisciplinary leadership - leadership of Huashan Hospital's neuro-oncology MDT, integrating neurosurgery, neuro-oncology, radiation oncology, neuroimaging, neurophysiology, and rehabilitation in a coordinated treatment planning process for every patient with a primary or metastatic brain tumor

The Case That Showed What Awake Craniotomy Delivers

The Situation

A 41-year-old algorithm engineer. Two months of progressive right leg weakness and word-finding difficulty. Three focal seizures affecting the right face. Left frontotemporal GBM 5.6 x 4.8 x 3.9 cm, with Broca's area and supplementary motor area activation overlapping the tumor's posterior margin on fMRI. Arcuate fasciculus compressed and displaced; CST displaced but intact on DTI. KPS 90. Boston Naming Test Z-score -1.4. A career that depended on language and executive function. MDT consensus: awake craniotomy with biphasic cortical and subcortical mapping, targeting EOR above 95%. One question: is there a neurosurgeon with the awake craniotomy experience, the intraoperative mapping expertise, and the functional preservation track record to achieve near-total resection in this patient without destroying what made his life worth living?

The Assessment

Dr. Zhou reviewed Mr. Li's complete multimodal imaging workup - the T1 contrast MRI, the fMRI activation maps, the DTI fiber tractography, the ASL perfusion data, and the neuropsychological assessment. He studied the spatial relationship between the tumor's posterior margin and Broca's area activation with the precision of a surgeon planning every millimeter of the resection. He reviewed the arcuate fasciculus trajectory: compressed and displaced medially, but intact - a pathway that could be preserved if the subcortical mapping was executed with sufficient precision.

His operative plan was defined before the first incision: left frontotemporal horseshoe craniotomy avoiding the superficial temporal artery, 3D neuronavigation fusing all functional and structural imaging modalities, AAA anesthetic technique, biphasic cortical and subcortical mapping with a 35 mm safety margin from all positive sites, CUSA ultrasonic aspiration combined with 5-ALA fluorescence guidance for tumor removal, and continuous subcortical stimulation tracking the arcuate fasciculus and CST throughout the deep resection phase.

He explained his approach to Mr. Li and his family directly:

"The tumor is in the part of your brain that controls your speech and your right hand. We cannot remove it safely under general anesthesia, because we cannot know in real time where the boundary is between tumor and the tissue that makes you who you are. During the awake phase, you will be talking to us - naming pictures, moving your fingers - while we stimulate the brain surface and the tissue beneath it. When the stimulation causes any change in your speech or your movement, we stop in that direction. That is how we find the boundary. That is how we take as much tumor as possible while keeping everything that matters."

The Procedure

Dr. Zhou led the operative team in an awake craniotomy with biphasic cortical and subcortical electrophysiological mapping and 5-ALA fluorescence-guided resection - total operative time 5.2 hours, estimated blood loss 280 mL, no transfusion required.

The craniotomy was performed under AAA anesthesia: propofol plus remifentanil TCI for the opening phase, transitioning to dexmedetomidine infusion with light propofol background for the awake mapping and resection phase. Mr. Li was cooperative, calm, and able to perform naming and motor tasks throughout the awake phase without agitation.

Cortical mapping was performed with bipolar stimulation (58 mA, 50 Hz, 2 ms pulse width), systematically stimulating the exposed cortex point by point. Sites producing naming interruption or speech errors were marked as language-positive. Sites producing right hand or face movement or EMG bursts were marked as motor-positive. A 35 mm safety margin from all positive sites defined the resection boundary.

Tumor resection proceeded with CUSA ultrasonic aspiration under 5-ALA fluorescence guidance - the pink-red fluorescence of tumor tissue distinguishable from the non-fluorescing normal brain in real time. As resection approached the deep margins, continuous subcortical bipolar stimulation (2-5 mA) tracked the arcuate fasciculus and CST. When subcortical stimulation of the posterior-inferior resection cavity produced a threshold response at 2 mA - indicating proximity to the CST - resection in that direction was stopped, preserving a functional isolation zone at the insular deep margin near the internal capsule.

The resection endpoint was determined by three concurrent criteria: fluorescence extinction concordant with navigation residual imaging, safe subcortical stimulation thresholds, and stable language and motor task performance throughout the final resection phase. Mr. Li named objects and moved his right hand correctly to the end of the procedure.

The Recovery

MRI within 24 hours of surgery showed enhancing residual volume of less than 0.4 cm3 - located at the deep insular margin near the internal capsule, where the CST threshold had reached 2 mA and active preservation had been chosen over further resection. EOR: 97.2%.

On postoperative day 1: mRS 1, NIHSS 0. No new aphasia. No new hemiplegia. Boston Naming Test Z-score had recovered to -0.6 - from -1.4 preoperatively - reflecting resolution of the mass effect that had been compressing his language network.

Final pathology confirmed: WHO CNS Grade 5 Glioblastoma, IDH wild-type, MGMT promoter unmethylated, TERT promoter mutated, EGFR amplified.

Adjuvant therapy followed the Stupp protocol: 60 Gy in 30 fractions with concurrent temozolomide. Given MGMT unmethylated status, the MDT recommended addition of Tumor Treating Fields (TTFields) and enrollment in a prospective molecular follow-up cohort.

At 6 and 12 months: MRI stable by RANO criteria. KPS 90. Mr. Li had returned to part-time work. EORTC QLQ-BN20 assessment confirmed well-maintained cognitive and communication function. PFS: 13.5 months, ongoing monitoring.

He sent a message to CMCS at his 12-month review. He wrote: "I went into that operating room not knowing if I would come out still able to do my job - or still able to be myself. I came out with my words intact, my hand working, and more of the tumor gone than I thought possible. Dr. Zhou gave me time. What I do with it is up to me."

Outcome Summary

• ✅ EOR 97.2% achieved - enhancing residual volume less than 0.4 cm3 at 24-hour post-operative MRI; active preservation of CST at insular deep margin where subcortical threshold reached 2 mA; near-total resection confirmed
• ✅ No new neurological deficit - mRS 1, NIHSS 0 on postoperative day 1; no new aphasia; no new hemiplegia; Boston Naming Test Z-score improved from -1.4 preoperatively to -0.6 postoperatively
• ✅ Real-time functional preservation confirmed intraoperatively - language and motor task performance stable throughout awake resection phase; subcortical CST tracking identified and respected functional boundary at 2 mA threshold
• ✅ KPS 90 at 12 months - MRI stable by RANO criteria; returned to part-time work; EORTC QLQ-BN20 confirmed well-maintained cognitive and communication function
• ✅ PFS 13.5 months, ongoing - Stupp protocol completed with TTFields addition for MGMT unmethylated disease; enrolled in prospective molecular follow-up cohort
• ✅ World-class outcome at a fraction of the cost - awake craniotomy with multimodal neuronavigation, biphasic cortical and subcortical mapping, 5-ALA fluorescence guidance, and AAA anesthesia in Shanghai at a fraction of US or European costs, with functional preservation outcomes that matched the world's leading eloquent cortex tumor surgery programs

"He was 41. A 5.6 cm glioblastoma growing into his language and motor cortex. His career depended on his ability to speak and think precisely. Dr. Zhou Liangfu at Huashan Hospital performed an awake craniotomy with real-time cortical and subcortical mapping - the patient naming objects and moving his hand throughout the resection. EOR reached 97.2% with no new neurological deficit. At 12 months, Mr. Li had returned to part-time work with language and motor function intact."

Why Shanghai for Brain Tumor Surgery?

• World-class outcomes at a fraction of the cost - awake craniotomy with multimodal neuronavigation, biphasic cortical and subcortical mapping, 5-ALA fluorescence guidance, and AAA anesthesia in Shanghai at a fraction of what it would cost in the US or Europe, with functional preservation outcomes that benchmark against the world's leading eloquent cortex tumor surgery programs
• Highest-volume neurosurgical center in China - Huashan Hospital is China's highest-volume neurosurgical center, with a brain tumor case volume that generates the operative experience, intraoperative monitoring infrastructure, and quality control systems that translate directly into superior functional preservation and resection extent outcomes; Dr. Zhou's personal awake craniotomy experience spans decades and encompasses the full spectrum of eloquent cortex tumor complexity
• Multimodal functional imaging integration as standard practice - the integration of fMRI, DTI fiber tractography, ASL perfusion, and 3D neuronavigation into a unified pre-operative planning framework is not universally available; at Huashan Hospital, multimodal functional imaging fusion is the standard pre-operative workup for every eloquent cortex tumor, ensuring that the intraoperative mapping strategy is informed by the most complete possible picture of the patient's functional anatomy
• Biphasic cortical and subcortical mapping as the institutional standard - many centers perform cortical mapping but do not systematically extend subcortical stimulation tracking into the white matter pathways during resection; Dr. Zhou's program performs biphasic mapping - cortical surface identification followed by continuous subcortical pathway tracking throughout the deep resection phase - as the standard technique for all eloquent cortex cases, enabling resection to proceed safely to the functional boundary rather than stopping at an arbitrary anatomical margin
• Integrated neuro-oncology pathway from surgery through adjuvant therapy - Mr. Li's surgical resection was embedded in a coordinated neuro-oncology pathway that included molecular profiling, MDT-guided adjuvant therapy selection (Stupp plus TTFields for MGMT unmethylated disease), and enrollment in a prospective molecular follow-up cohort; the surgical outcome is the foundation, but the long-term benefit depends on the quality of the entire treatment pathway that follows it

How CMCS Supports International Patients Seeking Brain Tumor Surgery in Shanghai

• 🏥 Specialist access - direct connection to Dr. Zhou Liangfu and Huashan Hospital's Department of Neurosurgery, including priority appointment coordination for patients with urgent or complex presentations
• 📋 MRI (T1 contrast, fMRI, DTI, ASL), PET imaging, pathology reports, molecular profiling results, and neuropsychological assessment records translation and coordination
• 🗣️ On-site medical interpretation at every consultation, procedure, and follow-up
• ✈️ Travel and logistics coordination - visa, accommodation, airport transfers
• 📞 24/7 concierge support from first inquiry through every stage of treatment
• 🔄 Post-treatment follow-up - MRI surveillance scheduling, adjuvant therapy coordination, TTFields support, neuropsychological follow-up coordination, and long-term neuro-oncology management support

📢 Subscribe to China Medical Concierge - Shanghai (CMCS)

We're delighted to offer you trusted medical tourism and personalized medical concierge services, giving you and your loved ones an extra pathway to quality care from China.

💬 Got questions? Drop a comment or DM us - we're always here to help!

📢 Have your own incredible medical story in China? Share it with us in the comments below!

#ChinaMedicalTour #AffordableHealthcare #MedicalTourismChina #ChinaHealthcare #MedicalConcierge #Glioblastoma #BrainTumor #AwakeCraniotomy #ZhouLiangfu #HuashanHospital

🤝 Connect With CMCS
Struggling with long medical waitlists? Facing barriers to overseas treatment? China Medical Concierge - Shanghai (CMCS) helps international patients access premium medical care in Shanghai's top public and private hospitals, with end-to-end personalized support.

Contact us for international patient support:
📧 contract@medicalsh.com | 🌐 medicalsh.com